American College of Cardiology

JANUARY 14, 2025

The optimal management of isolated, distal deep vein thrombosis (DVT) remains unclear. Data from recent studies suggest that certain patients may benefit from anticoagulation.

Thrombosis 43

Thrombosis Outcomes Article 43

American College of Cardiology

JANUARY 6, 2025

Subclinical leaflet thrombosis (SLT) has raised concerns about the long-term durability and outcomes of transcatheter aortic valve replacement (TAVR). Clinical valve thrombosis (CVT) is a rare complication after TAVR with an incidence of 0.62.8%

Thrombosis 40

Thrombosis TAVR Aortic valve Aortic 40

Frontiers in Cardiovascular Medicine

JULY 1, 2024

Notably, acute massive pulmonary embolism (PE) with bilateral atrial thrombosis is an exceptional occurrence in CAPS. Acute massive PE combined with bilateral atrial thrombosis has an even higher mortality rate. Acute pulmonary embolism (PE) is a common cardiovascular disease that progresses rapidly and has a high mortality rate.

Thrombosis 52

Thrombosis Embolism Pulmonary Laboratory 52

Stroke Journal

FEBRUARY 1, 2024

Background:Coronavirus disease 2019 (COVID-19) increases the risk of cerebral venous sinus thrombosis (CVST), and previous reports derived from small case series reported a high mortality in these patients, up to 40%. Median age did not differ between the groups (43 vs 44years,P=0.6)

COVID-19 40

COVID-19 Thrombosis Outcomes Hospital 40

Stroke Journal

JANUARY 30, 2025

Introduction:The majority of patients with cerebral venous thrombosis (CVT) achieve functional independence (modified Rankin Score [mRS] 0-2), although many continue to experience residual symptoms that negatively impact quality of life. Stroke, Volume 56, Issue Suppl_1 , Page AWP143-AWP143, February 1, 2025. vs 53.810.4;

Thrombosis 40

Thrombosis Stroke Strokes Outcomes 40

Stroke Journal

JANUARY 30, 2025

Background:Newer Oral Anticoagulants (NOACs) offer potential advantages for patients with cerebral venous sinus thrombosis (CVST). The primary outcome was recurrent thrombotic events during 6-month follow-up. Stroke, Volume 56, Issue Suppl_1 , Page AWP299-AWP299, February 1, 2025. vs 8.0%, P=0.014) and mRS2 (95.1%

Thrombosis 40

Thrombosis Hospital Outcomes Stroke 40

Heart BMJ

APRIL 15, 2024

Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0–30, 31–90, 91–180 and 181–365 days. Conclusions COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes.

COVID-19 98

COVID-19 Thrombosis Heart Failure Outcomes 98

CardiacWire

JANUARY 24, 2025

By inhibiting Factor XI (an anticoagulation enzyme), drugs like abelacimab potentially prevent thrombosis without increasing spontaneous bleeding risks. Unfortunately, DOACs often cause gastrointestinal bleeding, which prompted the development of new stroke-prevention methods like Factor XI inhibition. year follow-up.

Stroke 59

Stroke Strokes AFIB Thrombosis 59

Circulation

JANUARY 27, 2025

BACKGROUND:In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. points (P=0.36), respectively.

Thrombosis 40

Thrombosis Stent Stents Quality of Life 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

IntroductionCerebral venous sinus thrombosis (CVST) is a rare form of stroke that usually affects young females especially during pregnancy and the postpartum period. The symptoms of cerebral venous sinus thrombosis can vary depending on the location and extent of the clot. Only studies with sample sizes larger than 10 were included.

Thrombosis 40

Thrombosis Outcomes Cancer Risk Factors 40

Stroke Journal

FEBRUARY 1, 2024

Background:Direct oral anticoagulants (DOACs) are suitable for some patients with cerebral venous thrombosis (CVT). We examined duration of PA prior to DOAC initiation and outcomes in ACTION-CVT, an international retrospective study.Methods:We compared three groups: no lead-in PA, 1-4 days (d) of PA, and 5-21d of PA. 1-4d, 23.8%

Thrombosis 40

Thrombosis Outcomes Hemorrhage Stroke 40

Frontiers in Cardiovascular Medicine

MARCH 10, 2024

There are conflicting sources regarding the relationship between hyperglycemia and outcomes in STEMI patients. We aimed to compile evidence to assess the association between hyperglycemia and adverse outcomes. Mortality was the most often outcome reported related to hyperglycemia. 3.45) and 4.47 (95% CI: 2.54–7.87),

Myocardial Infarction 59

Myocardial Infarction Cardiogenic Shock Article STEMI 59

DAIC

JANUARY 11, 2024

Researchers analyze primary and secondary cardiovascular outcomes in 132,784 inpatients with COVID-19 (October 8, 2020 to September 30, 2021) and 31,173 inpatients with non-COVID-19 pneumonia (January 1, 2019 to December 31, 2019) in Korea. The results indicate a lower risk of cardiovascular disease in COVID-19 patients.

COVID-19 103

COVID-19 Hospital Thrombosis Inpatient 103

Stroke Journal

FEBRUARY 1, 2024

Introduction:Seizures are a common initial manifestation of cerebral venous thrombosis (CVT). The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. Variables with P-value < 0.2

Thrombosis 40

Thrombosis Risk Factors Hemorrhage Outcomes 40

Circulation

NOVEMBER 11, 2024

The outcome was any 30-day event defined as death, stent thrombosis, major bleeding events, and composites of ischemic and bleeding events. There was no statistically significant difference in death or composite outcomes between groups (Table 2).

Thrombosis 40

Thrombosis Outcomes Stent Stents 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

IntroductionCerebral sinus venous thrombosis (CSVT) has traditionally been treated medically with systemic anticoagulation. We included studies that reported outcomes following EVT for CSVT. The primary outcome of interest was rate of modified Rankin Scale (mRS) 0‐2.

Thrombosis 40

Thrombosis Outcomes Stroke Strokes 40

DAIC

JUNE 12, 2024

It enrolled 162 subjects at 30 centers with three patient populations – non-thrombotic iliac vein lesion (NIVL), post-thrombotic syndrome (PTS) and acute deep vein thrombosis (aDVT). Ultimately, the new device promises to enable excellent clinical outcomes and drive significant quality of life improvements.” Res Pract Thromb Haemost.

Stent 105

Stent Stents Anatomy Ultrasound 105

Journal of the American Heart Association

FEBRUARY 14, 2025

We compared procedural complications and clinical outcomes among patients <75 years of age (n=99), those 75 to 84 years of age (n=103), and those 85 years of age (n=71). Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration.

Aortic valve 40

Aortic valve Aortic TAVR Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

Introduction:Exposure to high altitude environment is a risk factor of cerebral venous thrombosis (CVT) probably due to the hypercoagulability. The risk factors, clinical and radiological presentations, treatment, and outcomes were analyzed.Results:A total of 43 patients with CVT from Tibet and 111 patients from PUMCH were included.

Thrombosis 40

Thrombosis Risk Factors Hospital Hemorrhage 40

DAIC

NOVEMBER 8, 2024

Venita Chandra, director of vascular surgery, Stanford University School of Medicine, showed that DA followed by DCB achieved a significantly lower provisional stent rate with comparable safety and efficacy outcomes compared to standard predilatation prior to DCB, making it a viable alternative for treating long and highly calcified lesions.

Stent 52

Stent Stents Angioplasty Peripheral Arterial Disease 52

Frontiers in Cardiovascular Medicine

MAY 29, 2024

This study investigates clinical outcomes, aortic remodeling, and abdominal aortic perfusion patterns after TEVAR with the novel Castor device.MethodsFrom November 2020 to June 2023, 29 patients with TBAD involving the LSA were treated with the Castor single-branched stent graft. Of the 102 abdominal aortic branches, 94.1%

Stent 52

Stent Stents Aortic Outcomes 52

Circulation

FEBRUARY 12, 2024

The 2 coprimary outcomes were target lesion revascularization and myocardial infarction. The secondary outcomes included ischemia-driven target lesion revascularization, target vessel myocardial infarction, death, cardiac death, target vessel revascularization, stent thrombosis, and major adverse cardiac events.

Ultrasound 67

Ultrasound Myocardial Infarction Thrombosis Stents 67

Cardiometabolic Health Congress

JANUARY 16, 2025

Precision Medicine: Personalizing Prevention for Better Outcomes Precision medicine provides tools to customize prevention and treatment plans based on individual risk factors. Precision medicine, primordial prevention, and addressing systemic barriers can improve outcomes and reduce the burden of CVD globally.

Atherosclerosis 59

Atherosclerosis Risk Factors Coronary Artery Disease Cardiovascular Disease 59

Circulation: Cardiovascular Interventions

JANUARY 24, 2024

Principal safety outcomes were independently adjudicated International Society on Thrombosis and Haemostasis major bleeding at 72 hours post-treatment and mortality within 12 months of treatment. However, utilization and safety of such strategies in broader PE populations remain unclear.

Embolism 75

Embolism Thrombolysis Ultrasound Pulmonary 75

Dr. Smith's ECG Blog

NOVEMBER 15, 2023

MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection; myocardial disorders, including myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies. This is in spite of the known proclivity of tighter stenoses to thrombose.

Coronary Angiogram 109

Coronary Angiogram Plaque Thrombosis STEMI 109

Journal of Cardiovascular Pharmacology

MAY 2, 2024

Patient characteristics and clinical outcomes were collected via electronic medical record system. The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stent thrombosis within 12 month.

Outcomes 40

Outcomes Myocardial Infarction Thrombosis Academic 40

Frontiers in Cardiovascular Medicine

JUNE 5, 2024

BackgroundBehcet's disease (BD) is a systematic vasculitis that affects vessels with various sizes, presenting as venous thrombosis and arterial pseudoaneurysms.

Embolism 52

Embolism Aortic Thrombosis Stent 52

Journal of Cardiothoracic Surgery

JULY 4, 2024

To compare the treatment outcomes among percutaneous mechanical thrombectomy (PMT) with AngioJet, Catheter-directed thrombolysis (CDT), and a combination of both.

Thrombolysis 40

Thrombolysis Thrombosis Outcomes Research 40

Open Heart

JUNE 18, 2024

The LEADERS FREE III (LF III) trial investigated clinical outcomes after PCI with the next-generation cobalt-chromium thin-strut polymer-free biolimus-coated stent (CoCr-BCS) in HBR patients. The primary safety endpoint was the composite of cardiac death (CD), myocardial infarction(MI) or definite/probable stent thrombosis (ST).

Stent 40

Stent Stents Outcomes Myocardial Infarction 40

Circulation: Cardiovascular Interventions

MARCH 30, 2025

However, whether the addition of OCT to angiography to guide percutaneous coronary intervention (PCI) of complex lesions affects clinical outcomes is debated.Methods:A systematic search for randomized controlled trials (RCTs) was conducted using PubMed, Scopus, and Cochrane databases through September 2024.

Thrombosis 40

Thrombosis Myocardial Infarction Stent Stents 40

Open Heart

JANUARY 6, 2022

Colchicine, a cheap and widely used anti-inflammatory has shown promise in improving cardiovascular outcomes. Results The use of colchicine in patients who underwent PCI significantly reduced MACE outcomes (risk ratio 0.73 (95% CI 0.61 This has been shown to increase the likelihood of further major adverse cardiovascular events (MACE).

Coronary Artery Disease 52

Coronary Artery Disease Thrombosis Stent Stents 52

DAIC

MARCH 31, 2025

Abelacimab is currently in Phase 3 development with the lead indication for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.

Atrial Fibrillation 52

Atrial Fibrillation BMI General Cardiology Thrombosis 52

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

This study aims to investigate the incidence, complications, and outcomes of SAH patients who develop HIT.MethodsICD‐9‐CM and ICD‐10‐CM codes were used to query the National Inpatient Sample for patients with SAH between 2010 and 2019. Patients with SAH are an understudied population in terms of assessing incidence and impact of HIT.

Hemorrhage 40

Hemorrhage Aneurysm Outcomes Thrombosis 40

Stroke Journal

FEBRUARY 1, 2024

Von Willebrand factor (VWF) plays a crucial role in hemostasis and thrombosis by promoting platelet adhesion to the subendothelial matrix and factor VIII stabilization. aureusinfected VWF-deficient mice exhibited reduced infarcts and better long-term functional outcomes (P <0.05 aureusor vehicle on days 0, 2, and 5.

Outcomes 40

Outcomes Stroke Strokes Thrombosis 40

Stroke Journal

JANUARY 30, 2025

However, long-term outcomes remain poorly described, and the prognostic significance of the radiographic findings is uncertain.Methods:We extracted demographics and clinical variables for all infants with DMVT at our institution from 2007 to 2023. Stroke, Volume 56, Issue Suppl_1 , Page ATMP85-ATMP85, February 1, 2025.

Thrombosis 40

Thrombosis Hemorrhage Congenital Outcomes 40

Stroke Journal

JANUARY 30, 2025

Migraine with aura(MwA) is associated with an increased risk of stroke and adverse vascular outcomes compared to those with migraine without aura (MwoA). Patients with any adverse vascular outcomes before the index ECG were excluded. The prevalences of all vascular outcomes are summarized in Table 1. p < 001).

Atrial Fibrillation 40

Atrial Fibrillation Outcomes Coronary Artery Disease Myocardial Infarction 40

Stroke Journal

OCTOBER 31, 2024

Thrombosis is the main pathological process of stroke and is therefore an important therapeutic target in stroke prevention. We review the concepts of stroke immunothrombosis and thromboinflammation and the effect of immune cells on vessel recanalization and patient outcome. Stroke, Ahead of Print.

Stroke 40

Stroke Strokes Thrombosis Plaque 40